Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: BELPHARMA s.a., 2, Rue Albert 1er, L-1117, Luxembourg, Grand Duchy of Luxembourg
Beromun 1 mg powder for solution for infusion.
Pharmaceutical Form |
---|
Powder for solution for infusion (powder for infusion). The powder is white to off-white. |
Each vial contains 1 mg tasonermin*, corresponding to 3.0-6.0 × 107 IU (International Units).
* tumor necrosis factor alfa-1a (TNFα-1a) produced by recombinant DNA technology in E. coli.
Excipient(s) with known effect: Each vial contains 20.12 mg (0.87 mmol) sodium. After reconstitution in 0.9% physiological sodium chloride solution the amount is 37.82 mg (1.64 mmol) sodium.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Tasonermin |
Tasonermin is cytotoxic or cytostatic in vitro for a variety of tumour cell lines of different histogenesis. Tasonermin affects the morphology and reduces proliferation of endothelial cells. Also, it has profound effects on cellular components of the immune system. |
List of Excipients |
---|
Sodium dihydrogen phosphate dihydrate |
Powder vial: Type I glass vial with chlorobutyl rubber stopper and sealed with aluminium flip-off cap.
Each pack contains 4 vials.
BELPHARMA s.a., 2, Rue Albert 1er, L-1117, Luxembourg, Grand Duchy of Luxembourg
EU/1/99/097/001
Date of first authorisation: 13 April 1999
Date of latest renewal: 13 April 2009
Drug | Countries | |
---|---|---|
BEROMUN | Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Lithuania, Poland, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.